Analysts Offer Predictions for OptimizeRx Co.’s Q1 2024 Earnings (NASDAQ:OPRX)

OptimizeRx Co. (NASDAQ:OPRX) – Research analysts at William Blair dropped their Q1 2024 earnings estimates for shares of OptimizeRx in a research report issued on Tuesday, April 16th. William Blair analyst R. Daniels now anticipates that the company will earn ($0.34) per share for the quarter, down from their previous estimate of ($0.29). The consensus estimate for OptimizeRx’s current full-year earnings is ($0.59) per share. William Blair also issued estimates for OptimizeRx’s Q2 2024 earnings at ($0.21) EPS, Q3 2024 earnings at ($0.04) EPS, Q4 2024 earnings at $0.06 EPS and FY2024 earnings at ($0.51) EPS.

Several other research firms have also issued reports on OPRX. Stifel Nicolaus reissued a “buy” rating and issued a $13.00 target price on shares of OptimizeRx in a report on Monday, April 1st. JMP Securities reissued a “market outperform” rating and issued a $15.00 target price on shares of OptimizeRx in a report on Tuesday. Barclays assumed coverage on shares of OptimizeRx in a report on Wednesday, January 3rd. They issued an “equal weight” rating and a $15.00 target price for the company. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 target price on shares of OptimizeRx in a report on Monday, April 1st. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $15.86.

OptimizeRx Stock Down 1.9 %

Shares of NASDAQ:OPRX opened at $9.35 on Thursday. The firm’s 50 day moving average price is $13.36 and its 200-day moving average price is $11.95. OptimizeRx has a twelve month low of $6.92 and a twelve month high of $16.65. The stock has a market capitalization of $169.98 million, a PE ratio of -9.26 and a beta of 0.98.

Institutional Trading of OptimizeRx

A number of institutional investors have recently bought and sold shares of the stock. UBS Group AG boosted its stake in shares of OptimizeRx by 290.0% during the third quarter. UBS Group AG now owns 1,997 shares of the company’s stock valued at $29,000 after purchasing an additional 1,485 shares during the period. Nisa Investment Advisors LLC boosted its stake in shares of OptimizeRx by 215.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company’s stock valued at $31,000 after purchasing an additional 1,462 shares during the period. Captrust Financial Advisors boosted its stake in shares of OptimizeRx by 248.8% during the second quarter. Captrust Financial Advisors now owns 1,287 shares of the company’s stock valued at $35,000 after purchasing an additional 918 shares during the period. Quantbot Technologies LP purchased a new stake in shares of OptimizeRx during the third quarter valued at $49,000. Finally, Point72 Hong Kong Ltd purchased a new stake in shares of OptimizeRx during the first quarter valued at $52,000. 76.47% of the stock is currently owned by institutional investors.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.